Is Saakshi Medtech overvalued or undervalued?

As of 20 August 2025, the valuation grade for Saakshi Medtech has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 72.31, an EV to EBIT ratio of 53.44, and an EV to EBITDA ratio of 33.28. These figures suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.
In comparison to its peers, Saakshi Medtech's PE ratio is notably higher than that of Adani Enterprises at 80.73 and SRF at 60.6, both categorized as very expensive, while Tata Chemicals, rated as attractive, has a PE ratio of 54.22. The company's recent stock performance has been underwhelming, with a year-to-date return of -12.32%, contrasting sharply with the Sensex's gain of 5.95% during the same period, further reinforcing the notion that Saakshi Medtech is overvalued in the current market environment.